RESUMEN
OBJECTIVE: To evaluate the association between Chinese medicine (CM) therapy and disease-free survival (DFS) outcomes in postoperative patients with non-small cell lung cancer (NSCLC). METHODS: This multiple-center prospective cohort study was conducted in 13 medical centers in China. Patients with stage I, II, or IIIA NSCLC who had undergone radical resection and received conventional postoperative treatment according to the National Comprehensive Cancer Network (NCCN) guidelines were recruited. The recruited patients were divided into a CM treatment group and a control group according to their wishes. Patients in the CM treatment group received continuous CM therapy for more than 6 months or until disease progression. Patients in the control group received CM therapy for less than 1 month. Follow-up was conducted over 3 years. The primary outcome was DFS, with recurrence/metastasis rates as a secondary outcome. RESULTS: Between May 2013 and August 2016, 503 patients were enrolled into the cohort; 266 were classified in the CM treatment group and 237 in the control group. Adjusting for covariates, high exposure to CM was associated with better DFS [hazard ratio (HR) = 0.417, 95% confidential interval (CI): 0.307-0.567)]. A longer duration of CM therapy (6-12 months, 12-18 months, >24 months) was associated with lower recurrence and metastasis rates (HR = 0.225, 0.119 and 0.083, respectively). In a subgroup exploratory analysis, CM therapy was also a protective factor of cancer recurrence and metastasis in both stage I-IIIA (HR=0.50, 95% CI: 0.37-0.67) and stage IIIA NSCLC postoperative patients (HR = 0.48, 95% CI: 0.33-0.71), DFS was even longer among CM treatment group patients. CONCLUSIONS: Longer duration of CM therapy could be considered a protective factor of cancer recurrence and metastasis. CM treatment is associated with improving survival outcomes of postoperative NSCLC patients in China. (Registration No. ChiCTR-OOC-14005398).
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/terapia , Neoplasias Pulmonares/terapia , Medicina Tradicional China , Cuidados Posoperatorios/métodos , Adulto , Anciano , Carcinoma de Pulmón de Células no Pequeñas/epidemiología , Carcinoma de Pulmón de Células no Pequeñas/cirugía , China/epidemiología , Estudios de Cohortes , Terapia Combinada/estadística & datos numéricos , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Neoplasias Pulmonares/epidemiología , Neoplasias Pulmonares/cirugía , Masculino , Medicina Tradicional China/métodos , Medicina Tradicional China/estadística & datos numéricos , Persona de Mediana Edad , Cuidados Posoperatorios/estadística & datos numéricos , Periodo Posoperatorio , Resultado del TratamientoRESUMEN
This study tested the effects of the antioxidant pyrrolidine dithiocarbamate on acute lung injury induced by cardiopulmonary bypass in rats. Adult rats were randomly divided into 3 groups of 7 each. The study group was pretreated with pyrrolidine dithiocarbamate before undergoing 60 min of normothermic partial cardiopulmonary bypass, a control group underwent cardiopulmonary bypass only, and a third group underwent a sham operation involving anesthesia and cannulation only. The respiratory index at 60 min after terminating bypass was significantly increased in the study group only. Neutrophil, malondialdehyde, interleukin-8, nuclear factor-kappaB, and protein levels in bronchoalveolar lavage fluid from the cardiopulmonary bypass group were significantly higher than those in the other two groups, with marked inflammatory changes on lung histopathology. It was concluded that cardiopulmonary bypass can directly induce acute lung injury, and pyrrolidine dithiocarbamate attenuates this injury by inhibiting nuclear factor-kappaB activity.
Asunto(s)
Antioxidantes/uso terapéutico , Puente Cardiopulmonar/efectos adversos , Pirrolidinas/uso terapéutico , Síndrome de Dificultad Respiratoria/prevención & control , Tiocarbamatos/uso terapéutico , Animales , Modelos Animales de Enfermedad , Femenino , Masculino , Modelos Cardiovasculares , FN-kappa B/antagonistas & inhibidores , Ratas , Ratas Sprague-Dawley , Síndrome de Dificultad Respiratoria/etiologíaRESUMEN
PURPOSE: During clinical monitoring, vecuronium appeared to reduce the rapidly extracted auditory evoked potentials index (A-line ARX index or AAI) to some extent. A prospective and randomized study was designed to analyze this phenomenon. METHODS: Forty adult patients undergoing elective surgery were studied. After tracheal intubation, anesthesia was maintained with an end-tidal isoflurane concentration (F(ET)ISO) of 1.0% for 20 min, then a 10-mL dose of either vecuronium 0.05 mg*kg(-1), 0.1 mg*kg(-1), 0.2 mg*kg(-1) or saline was administered in a randomized, double-blind design. The AAI and bispectral index (BI(hx)) were monitored throughout the study and analyzed off-line. RESULTS: BI(hx) was unaltered after the administration of saline or vecuronium. The mean of the averaged (per patient) AAI values recorded from two minutes to ten minutes after the administration of saline or vecuronium 0.05 mg*kg(-1) did not differ significantly from the corresponding mean recorded from 15 min to 20 min after F(ET)ISO maintained 1.0% (P = 0.678, 0.169), however after the administration of vecuronium 0.1 mg*kg(-1) or 0.2 mg*kg(-1), AAI was reduced from 18.3, 18.0 to 14.8, 13.4 (P = 0.016, 0.017). CONCLUSIONS: Neuromuscular block with vecuronium reduces AAI in patients during steady state anesthesia without surgical stimuli, while BI(hx) is unaltered. The cut-off values of AAI for events should be determined according to the level of neuromuscular blockade when monitoring the depth of anesthesia/sedation.